Too Much of a Good Thing With Dietary Supplements May Up Health Risks

A forum at the American Association for Cancer Research (AACR) Annual Meeting 2015 warns that use of over-the-counter dietary supplements may increase the risk of multiple health conditions and diseases if more than the recommended daily dosage is taken by patients.

New Guideline for Treating Patients After Their First Seizure

The American Academy of Neurology (AAN) and the American Epilepsy Society have released a new guideline for clinicians on treating patients who experience their first seizure, which will be presented at the AAN's 67th Annual Meeting in Washington, D.C.

Does Saline Nasal Irrigation Improve Symptoms of Acute URTIs?

A new review published in the Cochrane Library evaluated published randomized controlled trials (RCTs) comparing topical nasal saline treatment to other interventions in adults and children with clinically diagnosed acute URTIs.

Immune Checkpoint Inhibitors Promising in Melanoma

Pembrolizumab, ipilimumab, and other medications harness immune cells to target cancers

Changes Expected in Breast Cancer Rates

Overall, breast cancer could rise by as much as 50 percent within the next 15 years

Antibiotics Appear to Be Overused in NICUs

Big variation seen in prescribing rates, despite little difference in infection rates

Tips for Dealing with Difficult Patients

Good communication is crucial for managing encounters when denying a patient request

AHA Issues First Statement on CHD Management in Patients Over 40

The American Heart Association (AHA) has issued their first scientific statement on the diagnosis and management of patients over the age of 40 with congenital heart disease (CHD), which is designed to complement the 2008 American College of Cardiology (ACC)/AHA guidelines for adults with congenital heart disease (ACHD).

Study Tests Extending Natalizumab Dosing Schedule in MS Patients

Research indicates that extending the dose of Tysabri (natalizumab; Biogen) from 4 weeks up to 8 weeks may be well tolerated and effective in patients with multiple sclerosis (MS).

FDA-Approved Antifungal, Corticosteroid Could Potentially Play a Role in Treating MS

An antifungal and a corticosteroid already approved by the Food and Drug Administration (FDA) have shown promise in activating oligodendrocyte progenitor cells (OPCs) to stimulate myelin-producing cells and repair white matter that is damaged in multiple sclerosis (MS).